115 related articles for article (PubMed ID: 34802948)
1. Don't abandon BRAF-mutated patients with peritoneal metastasis! Re: « Therapeutic implications of B-RAF mutations in colorectal cancer ».
Noiret B; Piessen G; Eveno C
J Visc Surg; 2022 Feb; 159(1):85. PubMed ID: 34802948
[No Abstract] [Full Text] [Related]
2. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.
Cremolini C; Di Bartolomeo M; Amatu A; Antoniotti C; Moretto R; Berenato R; Perrone F; Tamborini E; Aprile G; Lonardi S; Sartore-Bianchi A; Fontanini G; Milione M; Lauricella C; Siena S; Falcone A; de Braud F; Loupakis F; Pietrantonio F
Ann Oncol; 2015 Oct; 26(10):2092-7. PubMed ID: 26153495
[TBL] [Abstract][Full Text] [Related]
3. Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.
Sasaki Y; Hamaguchi T; Yamada Y; Takahashi N; Shoji H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Nagai Y; Taniguchi H; Boku N; Ushijima T; Shimada Y
Asian Pac J Cancer Prev; 2016; 17(2):539-43. PubMed ID: 26925640
[TBL] [Abstract][Full Text] [Related]
4. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer.
Morris V; Overman MJ; Jiang ZQ; Garrett C; Agarwal S; Eng C; Kee B; Fogelman D; Dasari A; Wolff R; Maru D; Kopetz S
Clin Colorectal Cancer; 2014 Sep; 13(3):164-71. PubMed ID: 25069797
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L
Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Impact of Primary Side and RAS/RAF Mutations in a Surgical Series of Colorectal Cancer with Peritoneal Metastases.
Baratti D; Kusamura S; Niger M; Perrone F; Milione M; Cattaneo L; Guaglio M; Bartolini V; Pietrantonio F; Deraco M
Ann Surg Oncol; 2021 Jun; 28(6):3332-3342. PubMed ID: 32974694
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC.
Graf W; Cashin PH; Ghanipour L; Enblad M; Botling J; Terman A; Birgisson H
Ann Surg Oncol; 2020 Jan; 27(1):293-300. PubMed ID: 31571052
[TBL] [Abstract][Full Text] [Related]
8. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases.
Fujiyoshi K; Yamamoto G; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
Oncol Rep; 2017 Feb; 37(2):785-792. PubMed ID: 28000889
[TBL] [Abstract][Full Text] [Related]
9. New life for retrospective study in the precision oncology era.
Orlandi A; Basso M; Calegari MA; Barone C
Ann Oncol; 2015 Nov; 26(11):2352-3. PubMed ID: 26347104
[No Abstract] [Full Text] [Related]
10. Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer.
Christensen TD; Palshof JA; Larsen FO; Poulsen TS; Høgdall E; Pfeiffer P; Jensen BV; Yilmaz MK; Nielsen D
Acta Oncol; 2018 Aug; 57(8):1057-1062. PubMed ID: 29380640
[TBL] [Abstract][Full Text] [Related]
11. Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.
Ardighieri L; Zeppernick F; Hannibal CG; Vang R; Cope L; Junge J; Kjaer SK; Kurman RJ; Shih IeM
J Pathol; 2014 Jan; 232(1):16-22. PubMed ID: 24307542
[TBL] [Abstract][Full Text] [Related]
12. Epithelial-mesenchymal transition and somatic alteration in colorectal cancer with and without peritoneal carcinomatosis.
Shelygin YA; Pospekhova NI; Shubin VP; Kashnikov VN; Frolov SA; Sushkov OI; Achkasov SI; Tsukanov AS
Biomed Res Int; 2014; 2014():629496. PubMed ID: 25157365
[TBL] [Abstract][Full Text] [Related]
13. The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern.
Prasanna T; Karapetis CS; Roder D; Tie J; Padbury R; Price T; Wong R; Shapiro J; Nott L; Lee M; Chua YJ; Craft P; Piantadosi C; Sorich M; Gibbs P; Yip D
Acta Oncol; 2018 Nov; 57(11):1438-1444. PubMed ID: 30035653
[TBL] [Abstract][Full Text] [Related]
14. Reply to the letter to the editor 'new life for retrospective study in the precision oncology era' by Orlandi et al.
Pietrantonio F; Cremolini C
Ann Oncol; 2015 Nov; 26(11):2353. PubMed ID: 26347099
[No Abstract] [Full Text] [Related]
15. Extent of field change in colorectal cancers with BRAF mutation.
Poh A; Chang HS; Tan KY; Sam XX; Khoo A; Choo SN; Nga ME; Wan WK
Singapore Med J; 2018 Mar; 59(3):139-143. PubMed ID: 28210747
[TBL] [Abstract][Full Text] [Related]
16. Coaltered
Datta J; Smith JJ; Chatila WK; McAuliffe JC; Kandoth C; Vakiani E; Frankel TL; Ganesh K; Wasserman I; Lipsyc-Sharf M; Guillem J; Nash GM; Paty PB; Weiser MR; Saltz LB; Berger MF; Jarnagin WR; Balachandran V; Kingham TP; Kemeny NE; Cercek A; Garcia-Aguilar J; Taylor BS; Viale A; Yaeger R; Solit DB; Schultz N; D'Angelica MI
Clin Cancer Res; 2020 Mar; 26(5):1077-1085. PubMed ID: 31719050
[TBL] [Abstract][Full Text] [Related]
17. Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.
Al-Marrawi MY; Saroya BS; Brennan MC; Yang Z; Dykes TM; El-Deiry WS
Cancer Biol Ther; 2013 Aug; 14(8):703-10. PubMed ID: 23792568
[TBL] [Abstract][Full Text] [Related]
18. An amino-terminal
Tung JK; Neishaboori N; Haraldsdottir S; Suarez CJ
Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32669268
[TBL] [Abstract][Full Text] [Related]
19. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
[TBL] [Abstract][Full Text] [Related]
20. Mutations of RAS/RAF Proto-oncogenes Impair Survival After Cytoreductive Surgery and HIPEC for Peritoneal Metastasis of Colorectal Origin.
Schneider MA; Eden J; Pache B; Laminger F; Lopez-Lopez V; Steffen T; Hübner M; Kober F; Roka S; Campos PC; Roth L; Gupta A; Siebenhüner A; Kepenekian V; Passot G; Gertsch P; Glehen O; Lehmann K
Ann Surg; 2018 Nov; 268(5):845-853. PubMed ID: 30303876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]